RayzeBio and Neumora Therapeutics have successfully entered public markets, with both firms offering multiple drug candidates in clinical trials. RayzeBio’s IPO, the larger of the two, raised $311 million. The company targets radiation cancer therapies and has a lead program, RYZ101, for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Neumora raised $250 million for its ongoing pivotal testing of a novel major depressive disorder drug.
Cohesity Announces Data Security Posture Management
Cohesity and Normalyze have partnered to provide an integrated cyber recovery and ransomware protection solution with data security posture management capabilities. Aimed at discovering, classifying,
